A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Pemigatinib (Primary)
- Indications Lymphoid leukaemia; Lymphoma; Myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms FIGHT-203
- Sponsors Incyte Corporation
- 20 Sep 2024 Planned End Date changed from 31 Jul 2024 to 29 Oct 2024.
- 20 Sep 2024 Planned primary completion date changed from 31 Jul 2024 to 29 Oct 2024.
- 14 May 2024 According to Incyte media release, data from this trial will be presented at the European Hematology Association 2024